Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Astellas Gene Therapies
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
55.0%
+8.5% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:DominantThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
Novartis Gene Therapies
Competitor Displacement Rate
10.0%
Competitors are displacing Astellas Gene Therapies in 10.0% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: While a leader in gene therapy development, Astellas faces intense competition from other biopharma giants with significant R&D pipelines and established market presence in rare disease treatments.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[novartis.com][bluebirdbio.com]⚠️ Identified Vulnerability:Pipeline Depth
Primary Threat Identified:Novartis Gene Therapies
Target Persona:Patients with rare genetic disorders
🚨 Threat Velocity:7/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)